Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova GeneticsPRNewsWire • 07/05/22
Precigen to Participate in the 2022 H.C. Wainwright Global Investment ConferencePRNewsWire • 05/17/22
Precigen, Inc. (PGEN) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 05/02/22
Precigen Receives Fast Track Designation for PRGN-3006 UltraCAR-T® in Patients with Relapsed or Refractory Acute Myeloid LeukemiaPRNewsWire • 04/04/22
PRECIGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Precigen, Inc. f/k/a Intrexon Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 03/29/22
Precigen Provides Pipeline and Corporate Updates at the 40th Annual J.P. Morgan Healthcare ConferencePRNewsWire • 01/12/22
Here's Why Precigen, Inc. (PGEN) Could be Great Choice for a Bottom FisherZacks Investment Research • 01/11/22
Precigen: A Substantially Undervalued And Differentiated Gene Therapy CompanySeeking Alpha • 01/10/22
Precigen Announces Positive Interim Phase 1 Data for PRGN-3006 UltraCAR-T® in Relapsed or Refractory Acute Myeloid LeukemiaPRNewsWire • 12/13/21
Is the Options Market Predicting a Spike in Precigen (PGEN) Stock?Zacks Investment Research • 11/24/21
Precigen Achieves Significant Clinical Progress for UltraCAR-T® and AdenoVerse™ TherapiesPRNewsWire • 11/04/21
Precigen to Host R&D Update Virtual Event on November 4th to Share Clinical DevelopmentsPRNewsWire • 10/27/21
Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for PRGN-3007 UltraCAR-T® in Advanced ROR1+ Hematological and Solid TumorsPRNewsWire • 10/26/21